S

Sanofi

Global pharma company; vaccines and R&D

Thought Leader Liaison Gastroenterology

Full-TimeUpdated on 10/23/2026Deadline 12/15/26
$146.3k - $211.3k
Senior
Bachelor's, Master's
Charlotte, NC, USA
RemoteField-based role covering North and South Carolina, Alabama, Tennessee, and Kentucky; travel 60–80%. US and Puerto Rico residents only
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree is required.
  • A minimum of five years of work experience in one or more of the following is required: field sales, product marketing, or medical or clinical experience in the same or a related therapeutic area within the pharmaceutical or medical device industry.
  • GI and/or biologic marketplace experience is required.
  • A valid driver's license is required.
  • Ability to travel 60–80 percent and to travel to meetings, trainings, and programs as necessary is required.
  • The role must work within label and regulatory and legal compliance guidelines.
Responsibilities
  • Align with cross-functional account plans and teams, and orchestrate resources with the top 10–15 percent of KOLs as assigned by the HTLL.
  • Identify, profile, cultivate, and maintain long-term relationships with KOLs within the GI community.
  • Conduct substantial on-label business conversations about topics such as product, disease state, and company at appropriate venues outside the office setting.
  • Execute unique, on-label, and approved KOL programming, such as disease-state education for fellowship programs.
  • Collaborate and communicate compliantly with the field commercial team on each assigned KOL to ensure strategic and tactical cohesiveness.
  • Serve as a single point of contact to resolve KOL issues when directed by the HTLL and/or Headquarters.
  • Execute a customer-centric, needs-based approach with targeted KOLs.
  • Assist with on-label KOL development, including speakers, using approved decks and materials.
  • Orchestrate KOL executive encounters and engagement.
  • Plan and execute KOL engagements and executive encounters at local, regional, and national conferences, POAs, in-field engagements, and other venues as directed, in a compliant manner.
  • Act as a liaison between KOLs and home-office cross-functional teams.
  • Work with targeted KOLs to obtain feedback on GI Franchise and brand-related marketing strategies or materials; all materials and programs for which feedback is requested must be approved by legal, compliance, and regulatory.
  • Provide feedback to commercial leadership on various topics as requested.
  • Become the single point of contact for high-volume speaker logistics or scheduling and work cross-functionally to ensure appropriate communication.
  • Provide advisory board participant recommendations.
  • Provide speaker recommendations to marketing when requested.
  • Assist in the execution of commercial contracts when requested.
  • Execute and lead specific TLL initiatives to support the brand strategy.
  • Collaborate with relevant stakeholders and teammates.
  • Collaborate with TLLs across the Alliance.
  • Lead TLL projects and initiatives.
Desired Qualifications
  • A master's degree is preferred.
  • Launch experience is preferred.
  • Marketing experience is preferred.
  • Demonstrated leadership skills are preferred.
  • Ability to assemble and lead cross-functional teams toward a shared vision of success is preferred.
  • Ability to execute strategic and tactical plans under tight timelines is preferred.
  • Ability to present ideas effectively to individuals or groups, tailoring presentations to audience needs, is preferred.
  • Strong organizational skills are preferred.
  • Strong project management experience, including superior analytical and planning skills, is preferred.
  • Ability to manage multiple projects simultaneously is preferred.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...